Study Finds Synergism With Olaparib/Neratinib Combo in HER2+ Uterine Serous Carcinoma

Ghanshyam Yadav, MD

Ghanshyam Yadav, MD

In new preclinical data, the combination of the PARP inhibitor olaparib (Lynparza) and the pan-HER TKI neratinib (Nerlynx) was found to be highly synergistic in HER2-positive uterine serous carcinoma, according to lead study author Ghanshyam Yadav, MD.

About 30% of uterine serous carcinomas overexpress HER2. Previous research has found that patients with breast cancer who had high levels of HER2 expression were sensitized to PARP inhibitors, regardless ofBRCAstatus.

For the olaparib/neratinib study, the investigators conducted cell viability experiments with the agents both alone and in combination through the use of flow cytometry—based assays. They evaluated the synergism of the combination using CompuSyn software. Immunoblotting experiments were also conducted in order to illuminate the mechanism of drug activity. Last, the team used 2 HER2-positive uterine serous carcinoma xenografts to compare the efficacy of the combination with their use as monotherapy.

Results showed that the use of olaparib in combination with neratinib was more effective in inhibiting cell growth compared with each agent alone (P<.05). The combination also proved to be highly synergistic inHER2-amplified tumors—ARK-1 and ARK-2&mdash;in vitro. However, the combination did not appear to have any impact on ARK-4, which does not have anyHER2amplification.

Further, with neratinib, investigators noticed an increase in PAR expression in both uterine serous carcinoma cell lines, which implies that increased PAR activity may be one of the mechanisms responsible for the combination&rsquo;s synergistic effect. There were also increased levels of HER2 in cells that received single-agent olaparib.

Findings from the uterine serous carcinoma xenograft models revealed that the combination led to more potent tumor inhibition and had a more durable effect compared with single-agent olaparib or neratinib, as well as the untreated control (P<.05).

In an interview withTargeted Oncology,Yadav, a first-year resident at Baylor College of Medicine, further explored the rationale for this combination, the implications of the findings, and the next steps for this research.

TARGETED ONCOLOGY:Could you provide some background on the past research that led up to this study?

Yadav: My lab has worked on using TKIs in uterine serous cancers and they were shown to work pretty well. There was a paper done in breast cancer where they saw that once you inhibit PI3K, which is one of the downstream molecules in the pathway, there are also some changes going on inBRCA. [We had previously] thought that maybe these 2 pathways look entirely different. [Neratinib inhibits] the HER/ErbB2 pathway and olaparib inhibits the DNA damage repair pathway. [However, then] we hypothesized that maybe there is some connection between the 2 pathways. That&rsquo;s why we started investigating this.

Then, we found out that once you treat the cell with a PARP inhibitor, it increases HER2 expression on the cell surface, which essentially provides more target to neratinib. We found out that when these cells were treated with neratinib, there was an increase in PAR expression; PAR is basically the active part of PARP. This suggested that there was more DNA damage done. If you take away the PARP, which helps with DNA damage repair, you cause more damage; that's why the combination was very synergistic. After that, we did a mice study and we found that there was a significantly longer survival and statistically significant differences in tumor growth right from day 4 in one of our cell lines. We saw very strong synergism.

TARGETED ONCOLOGY:Could you expand on the combination of olaparib and neratinib?

Yadav: The rationale came from the study that was done in breast cancer; we wanted to see if these two pathways overlap. When we started, we first found out that [the PARP inhibitor] increases the expression of HER2 on the surface. We took a cell, we treated it with a PARP inhibitor, and we saw that there was increased HER2. We thought we could then see whether HER2 inhibitors could help. We didn't even know about the whole PAR thing until much later, which is when we were convinced that there has to be synergy. We started off [thinking] that olaparib helped neratinib. However, we also found out that neratinib is helping olaparib in different ways. That&rsquo;s why we were convinced that there was definitely something [going on] there.

We had 2 animal models, but this [work] is restricted only to uterine serous cancers which overexpress HER2. About 30% of these uterine serous cancers overexpress HER2, and the more HER2 that they express, the more aggressive they are.

TARGETED ONCOLOGY:What were the key takeaways from this study?

Yadav: What we have found so far is that the drugs are not very toxic to mice. We saw that the single-agent groups were absolutely useless, for lack of a better word, when it came to these 2 cell lines because the lines were very aggressive. However, we found that if you give both of these drugs at the same time, there is this synergism. The mice were doing well; they looked so much better. Not only did the medications prevent the tumor from growing, they shrank the tumor.

TARGETED ONCOLOGY:What are the next steps for this research? Is a first-in-human trial planned?

Yadav: As of now, we're looking into getting this work published. There are so many pieces coming together. However, I would like to see this being done in human subjects. In 1 year, I'm glad that we could accomplish what we did. Hopefully, this work will get published and then move forward to a clinical trial. We also need to know more about why this is happening. We know this happens, but we don't really know why exactly, so that would be the next step.

Reference:

Yadav G, Lopez S, Han C, et al. The combination of olaparib (poly (ADP-ribose) polymerase inhibitor) with neratinib (pan c-erb inhibitor) is highly synergistic in uterine serous carcinoma overexpressing HER2/neu. Presented at: 2019 SGO Annual Meeting; March 16-19, 2019; Honolulu, HI. Abstract 67.